Seres Therapeutics, Inc. (MCRB) Scheduled to Post Quarterly Earnings on Wednesday
Seres Therapeutics, Inc. (NASDAQ:MCRB) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.00 million. During the same quarter last year, the company earned ($0.70) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts expect Seres Therapeutics to post $-2.51 EPS for the current fiscal year and $-2.79 EPS for the next fiscal year.
Shares of Seres Therapeutics, Inc. (NASDAQ MCRB) opened at 10.04 on Wednesday. The company has a 50-day moving average of $12.76 and a 200 day moving average of $12.82. Seres Therapeutics, Inc. has a 52-week low of $8.85 and a 52-week high of $17.42. The stock’s market cap is $406.74 million.
A number of equities analysts have commented on MCRB shares. Seaport Global Securities reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a report on Friday, October 6th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. ValuEngine downgraded shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Friday, July 14th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $18.00.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/01/seres-therapeutics-inc-mcrb-scheduled-to-post-quarterly-earnings-on-wednesday.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.